Davide Corti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5170634/publications.pdf

Version: 2024-02-01

92 papers	24,038 citations	22153 59 h-index	51608 86 g-index
129 all docs	129 docs citations	129 times ranked	24900 citing authors

#	Article	IF	Citations
1	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583, 290-295.	27.8	1,695
2	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	28.9	1,195
3	A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science, 2011, 333, 850-856.	12.6	1,092
4	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	27.8	1,041
5	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	27.8	917
6	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726.	30.7	838
7	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021, 184, 2332-2347.e16.	28.9	784
8	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	27.8	756
9	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science, 2016, 353, 823-826.	12.6	675
10	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141.	27.8	648
11	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine, 2022, 28, 490-495.	30.7	577
12	Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell, 2019, 176, 1026-1039.e15.	28.9	558
13	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	28.9	541
14	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	12.6	504
15	Broadly Neutralizing Antiviral Antibodies. Annual Review of Immunology, 2013, 31, 705-742.	21.8	447
16	A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 2020, 584, 353-363.	27.8	413
17	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science, 2022, 375, 864-868.	12.6	394
18	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science, 2021, 373, 648-654.	12.6	385

#	Article	IF	Citations
19	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature, 2021, 597, 97-102.	27.8	385
20	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host and Microbe, 2020, 28, 475-485.e5.	11.0	380
21	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35, 109292.	6.4	375
22	SARS-like WIV1-CoV poised for human emergence. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3048-3053.	7.1	373
23	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science, 2016, 351, 1339-1342.	12.6	370
24	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature, 2021, 595, 707-712.	27.8	363
25	Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Cell, 2016, 166, 596-608.	28.9	320
26	Tackling COVID-19 with neutralizing monoclonal antibodies. Cell, 2021, 184, 3086-3108.	28.9	309
27	Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature, 2014, 516, 418-422.	27.8	300
28	Broad betacoronavirus neutralization by a stem helixâ€“specific human antibody. Science, 2021, 373, 1109-1116.	12.6	262
29	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	27.8	260
30	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science, 2021, 374, 1621-1626.	12.6	232
31	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature, 2021, 598, 342-347.	27.8	230
32	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature, 2021, 596, 103-108.	27.8	222
33	Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature, 2013, 501, 439-443.	27.8	220
34	Broad sarbecovirus neutralization by a human monoclonal antibody. Nature, 2021, 597, 103-108.	27.8	220
35	Clonal dissection of the human memory Bâ€cell repertoire following infection and vaccination. European Journal of Immunology, 2009, 39, 1260-1270.	2.9	200
36	Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10473-10478.	7.1	198

#	Article	IF	Citations
37	Platelet-derived growth factor-Î± receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nature Microbiology, 2016, 1, 16082.	13.3	170
38	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell, 2022, 185, 872-880.e3.	28.9	165
39	Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8384-8389.	7.1	161
40	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nature Structural and Molecular Biology, 2020, 27, 942-949.	8.2	153
41	Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge. Journal of Virology, 2008, 82, 3220-3235.	3.4	144
42	A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens. Nature, 2016, 529, 105-109.	27.8	140
43	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science, 2022, 377, 420-424.	12.6	140
44	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	28.9	131
45	Tackling influenza with broadly neutralizing antibodies. Current Opinion in Virology, 2017, 24, 60-69.	5.4	121
46	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell, 2017, 171, 229-241.e15.	28.9	118
47	Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17965-17970.	7.1	116
48	Influenza hemagglutinin membrane anchor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10112-10117.	7.1	115
49	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science, 2022, 375, 449-454.	12.6	108
50	Predicting the mutational drivers of future SARS-CoV-2 variants of concern. Science Translational Medicine, 2022, 14, eabk3445.	12.4	101
51	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	27.8	101
52	Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature, 2020, 588, 485-490.	27.8	95
53	Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations. Cell Host and Microbe, 2019, 25, 367-376.e5.	11.0	93
54	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nature Communications, 2022, 13, .	12.8	93

#	Article	IF	Citations
55	Human monoclonal antibodies by immortalization of memory B cells. Current Opinion in Biotechnology, 2007, 18, 523-528.	6.6	89
56	Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus. Journal of Infectious Diseases, 2010, 201, 946-955.	4.0	88
57	Capsid protein structure in Zika virus reveals the flavivirus assembly process. Nature Communications, 2020, 11, 895.	12.8	85
58	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science, 2022, 377, 735-742.	12.6	85
59	Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41. PLoS Pathogens, 2010, 6, e1001195.	4.7	82
60	Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nature Communications, 2015, 6, 7375.	12.8	74
61	Development of broadâ€spectrum human monoclonal antibodies for rabies postâ€exposure prophylaxis. EMBO Molecular Medicine, 2016, 8, 407-421.	6.9	73
62	Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae. Nature Communications, 2017, 8, 1991.	12.8	70
63	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1â€“4. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12265-12270.	7.1	70
64	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Regional Health - Europe, The, 2021, 1, 100013.	5.6	66
65	Discovery and Characterization of Spike Nâ€Terminal Domainâ€Binding Aptamers for Rapid SARSâ€CoVâ€2 Detection. Angewandte Chemie - International Edition, 2021, 60, 21211-21215.	13.8	62
66	Comparison of Four Serological Methods and Two Reverse Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. Journal of Clinical Microbiology, 2018, 56, .	3.9	58
67	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host and Microbe, 2019, 26, 623-637.e8.	11.0	56
68	Antibody-guided vaccine design: identification of protective epitopes. Current Opinion in Immunology, 2016, 41, 62-67.	5.5	53
69	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. PLoS Pathogens, 2022, 18, e1010248.	4.7	48
70	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. Microbiology Spectrum, 2014, 2, .	3.0	39
71	Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9430-9435.	7.1	38
72	Protection of calves by a prefusion-stabilized bovine RSV F vaccine. Npj Vaccines, 2017, 2, 7.	6.0	38

#	Article	IF	Citations
73	Alternative conformations of a major antigenic site on RSV F. PLoS Pathogens, 2019, 15, e1007944.	4.7	29
74	Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight, 2017, 2, .	5.0	29
75	Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. Nature Communications, 2020, 11, 596.	12.8	28
76	A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Molecular Medicine, 2020, 12, e12628.	6.9	26
77	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. Cell, 2022, 185, 2279-2291.e17.	28.9	25
78	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328.	2.5	21
79	Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Current Opinion in Virology, 2022, 53, 101204.	5.4	21
80	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	20
81	Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. Frontiers in Immunology, 2018, 9, 865.	4.8	19
82	AncesTree: An interactive immunoglobulin lineage tree visualizer. PLoS Computational Biology, 2020, 16, e1007731.	3.2	18
83	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. SSRN Electronic Journal, 2020, , 3606354.	0.4	16
84	Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science Advances, 2022, 8, .	10.3	16
85	Discovery and Characterization of Spike Nâ€Terminal Domainâ€Binding Aptamers for Rapid SARSâ€CoVâ€2 Detection. Angewandte Chemie, 2021, 133, 21381-21385.	2.0	14
86	Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. Antiviral Research, 2019, 163, 70-74.	4.1	8
87	Exceptionally potent human monoclonal antibodies are effective for prophylaxis and treatment of tetanus in mice. Journal of Clinical Investigation, 2021, 131, .	8.2	8
88	Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells. , 0, , 129-139.		1
89	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
90	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0

#	Article	IF	Citations
91	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0
92	AncesTree: An interactive immunoglobulin lineage tree visualizer. , 2020, 16, e1007731.		0